- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Transcept Pharmaceuticals Inc
+ Add to WatchlistTSPT:US
3.1600 USD 0.0700 2.27%As of 20:10:00 ET on 05/17/2013.
Snapshot for Transcept Pharmaceuticals Inc (TSPT)
| Open: | 3.1500 | Day's Range: | 3.0600 - 3.2000 | Volume: | 139,749 |
|---|---|---|---|---|---|
| Previous Close: | 3.0900 | 52wk Range: | 3.0500 - 7.4500 | 1-Yr Rtn: | -54.79% |
Key Statistics for TSPT
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.9600 |
| Est. EPS (USD) (12/2013) | -1.2350 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 59.27 |
| Shares Outstanding (M) | 18.76 |
| 30 Day Average Volume | 154,950 |
| Price/Book (mrq) | 0.6898 |
| Price/Sale (ttm) | 5.0809 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/13/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for TSPT
Company Profile & Key Executives for TSPT
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company which develops and commercializes proprietary products that address therapeutic needs in the fields of psychiatry and sleep medicine. The Company's products include sublingual low dose formulation of zolpidem developed for the treatment of insomnia.
| Glenn A OclassenPresident/CEO | Thomas P SolowayExec VP/COO/Co-Founder |
| Nikhilesh N SinghSenior VP/Chief Scientific Officer | John A KollinsSenior VP/Chief Business Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
TSPT News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page